Letrozole CAS 112809-51-5 API Factory Aromatase Inhibitor II High Quality
Supply with High Purity and Stable Quality
Chemical Name: Letrozole
CAS: 112809-51-5
Aromatase Inhibitor II
API High Quality, Commercial Production
| Chemical Name | Letrozole |
| Synonyms | CGS-20267; Femara |
| CAS Number | 112809-51-5 |
| CAT Number | RF-API86 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C17H11N5 |
| Molecular Weight | 285.3 |
| Melting Point | 181.0 to 183.0℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Solubility | Freely Soluble in Dichloromethane, Slightly Soluble in Ethanol and Practically Insoluble in Water |
| Identification IR | Spectrum of the sample corresponds to that of reference standard |
| Identification HPLC | The retention time of the test sample corresponds to that of the reference standard |
| Water Content (by K.F) | ≤0.30% |
| Residue on Ignition | ≤0.10% |
| Related Substances | |
| Related Substances A | ≤0.30% |
| Related Substances B | ≤0.20% |
| Any Unspecified Impurity | ≤0.10% |
| Total Unspecified Impurities | ≤0.30% |
| Total Impurities | ≤0.50% |
| Residual Solvents | |
| Ethyl Acetate | ≤0.50% |
| Methanol | ≤0.30% |
| Ethanol | ≤0.50% |
| DMF | ≤0.088% |
| Heavy Metals | ≤10ppm |
| Assay | 98.0%~102.0% (on the anhydrous basis ) |
| Shelf Life | 24 Months |
| Test Standard | Enterprise Standard |
| Usage | API, Aromatase Inhibitor II |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Letrozole (CAS 112809-51-5) is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment.
